NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis
Aim: To assess NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis.
Background: Hyperdynamic circulation is common in decompensated cirrhosis. The previous studies reveal that N-terminal-proBNP
(NT-proBNP) is elevated in cirrhosis.
Methods: A prospective study involved 47 patients with decompensated cirrhosis. All of them underwent echocardiography with
simultaneous measurement of blood pressure and heart rate. Cardiac output and systemic vascular resistance were calculated. The
concentration of NT-proBNP in blood was measured with enzyme-linked immunosorbent assay.
Results: In patients with decompensated cirrhosis, the concentration of NT-proBNP in blood directly correlated with end-diastolic
volume (r=0.482; p<0.001), stroke volume (r= 0.566; p<0.001), cardiac output (r=0.556; p<0.001), volume of the left atrium
(r=0.292; p=0.047), and inversely correlated with systemic vascular resistance (r=-0.538; p<0.001). There was no significant
correlation between NT-proBNP and ejection fraction (p=0.083). Patients with hyperdynamic circulation have higher concentration of
NT-proBNP (152÷476 pg/ml vs. 31÷133 pg/ml, p<0.001) regardless of the presence of diastolic dysfunction (p=0.222). According to
ROC analysis, the best cut-off values for detection of hyperdynamic circulation in decompensated cirrhosis are considered to be 170.0
pg/ml of blood NT-proBNP, showing sensitivity and specificity of 72.0 and 86.4%, respectively. The positive and negative predictive
value are 86.4% and 73.1%, AUC = 0.829 (0.709-0.949).
Conclusion: NT-proBNP may serve as a non-invasive biomarker for hyperdynamic circulation in decompensated cirrhosis.
Keywords: Blood circulation, Liver cirrhosis, Biomarkers, Natriuretic peptide, Brain.
(Please cite as: Maslennikov R, Driga A, Ivashkin K, Ivashkin V. NT-proBNP as a biomarker for hyperdynamic
circulation in decompensated cirrhosis. Gastroenterol Hepatol Bed Bench 2018;11(4):325-332).
Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest 1953; 32: 1025-33.
Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358-3670.
Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121-31.
Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017;66(4):849-859.
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28:89–94.
Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 1983; 117:859–865.
Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332:78–81.
Ogawa Y, Nakao K, Mukoyama M, et al. Rat brain natriuretic peptide—tissue distribution and molecular form. Endocrinology 1990; 126:2225–2227.
Ogawa Y, Nakao K, Mukoyama M, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 1991; 69:491–500.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;
La villa G, Romanelli RG, Casini raggi V, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology. 1992;16(1):156-6.
Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52(10):1511-7.
Raedle-hurst TM, Welsch C, Forestier N, et al. Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2008;20(9):865-73.
Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. Clin Sci. 2001;101(6):621-8.
Hirose S, Hagiwara H, Takei Y. Comparative molecular biology of natriuretic peptide receptors. Can J Physiol Pharmacol. 2001;79(8):665-72.
Maslennikov R.V., Driga A.A., Ivashkin K.V., Zharkova M.S., Mayevskaya M.V., Pavlov Ch.S., Arslanyan M.G., Musina N.B., Berezina E.N., Ivashkin V.T. Small intestinal bacterial overgrowth syndrome and systemic inflammation in pathogenesis of hemodynamic changes at liver cirrhosis. Ross z gastroenterol gepatol koloproktol 2017; 27(3):45-56.
Vuolteenaho O., Ala-Kopsala M., Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem 2005; 40: 1–36.
Lang RM, Badano LP, Moravi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.
Jeong EM, Dudley SC. Diastolic dysfunction. Circ J. 2015;79(3):470-7.
Prastaro M, Paolillo S, Savarese G, et al. N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction. Eur J Echocardiogr. 2011;12(7):506-13.
Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272-84.